Matthew Klipstein: Founder and CEO

Mr. Klipstein graduated with Honors from the University of California at Berkeley and from the University of Colorado School of Law.

Following law school, Mr. Klipstein was a Law Clerk to The Hon. Hatfield Chilson, United States District Judge, District of Colorado. Thereafter, he returned to San Francisco where he was co-founder and a partner in the law firm of Wolfe & Klipstein. After eight years, Mr. Klipstein retired from the practice of law and co-founded Digital Stock, Inc. a pioneer and industry leader in digital storage and distribution of high quality stock photography. Five years later Digital Stock was acquired by Bill Gates’ Corbis Corporation. Mr. Klipstein founded NeuroRepair, Inc. in 2004.


James Fallon, Ph.D.: Chief Science Officer

Dr. Fallon is Professor Emeritus of Anatomy and Neurobiology at the University of California, Irvine. He is a Sloan and NIH RCDA Research Scholar and holds Doctoris Honoris and Research Excellence and Teaching Awards from multiple institutions. He is a Senior Research  Fulbright Fellow. He has been elected President of the UC Irvine Faculty and Chair of the Medical School faculty and is the developer of numerous novel medical and research training models.

Dr. Fallon discovered a characterized growth factor in the mammalian brain (1984) and was first to demonstrate how to mobilize significant numbers of adult stem cells and progenitors in the injured brain (1997, 2000), a unique finding highlighted in the NIH Stem Cell report to Congress.

His lab localized EGF, TGFα, and bFGF in the brain. He has written broadly on schizophrenia, addiction, and the basal ganglia, limbic system, and cortex. He was the neuroanatomist on the team that discovered the presence of extensive postnatal development of new neurons in the human brain, a discovery that was noted as one of the most startling and important findings during the decade of the brain.

Dr. Fallon carried out his doctoral training in Neuroanatomy and Neurophysiology at the University of Illinois and his postdoctoral training at the University of California, San Diego.

Darius Gleason, Ph.D.

Dr. Gleason received his Ph.D. from the University of California Irvine where he studied neural stem cell identity in the laboratories of Peter J. Bryant and James H. Fallon. Dr. Gleason was also a California Institute for Regenerative Medicine Fellow from 2006 to 2009.

In 2008 his work with Transforming Growth Factor alpha (TGFα) in a model of Parkinson’s disease led to the landmark finding that ependymal cells in the adult brain can be stimulated to divide and to contribute rapidly dividing daughter cells into the subventricular zone.

Dr. Gleason received a Young Investigator Award for this work at the NSCs and Regeneration Biosymposia in Boston. Dr. Gleason has also studied the therapeutic potential of TGFα in a model of stroke and found that, similar to the Parkinson’s disease model, treatment of even chronic stroke injuries with TGFα induces massive proliferation, migration and differentiation of adult neural stem cells and progenitors. Dr. Gleason also has a JD from the University of Southern California.

Dr. Jay Short

Dr. Short was a founder of Diversa Corporation (NASDAQ: DVSA) where, over his 11 year tenure, he served in multiple roles including CEO, President, Chief Technology Officer, and Director. Dr. Short led the company’s highly successful initial public offering, which raised over $200 million in gross proceeds – the largest biotechnology IPO ever completed at the time. During his tenure as CEO, his team also raised $300 million in committed funding from corporate partners that included Novartis, Syngenta, Dow, Merck, Dupont, Givaudan, and Cargill. Diversa utilizes genomic technologies for discovery and optimization of novel products from genes derived from microbial diversity for industrial, chemical, agricultural and pharmaceutical applications. The company has been recognized as a member of the Deloitte and Touche’s Orange County / San Diego Technology “Fast 50’ for each year following its IPO. Before joining Diversa Corporation, Dr. Short served as President of Stratacyte, Inc. and Vice President of Research & Development and Operations for Stratagene Cloning Systems, a molecular biology company based in La Jolla, California. Dr. Short earned his Ph.D. in Biochemistry at Case Western Reserve University and his BA in chemistry with honors at Taylor University. Dr. Short received San Diego’s 2001 Ernst & Young Entrepreneur of the Year Award in Health Sciences and was the recipient of two first place awards granted by the University of California, San Diego, Connect Program.

In addition, Dr. Short’s grant program was selected as one of the top one percent of research programs in the United States for commercializing new products funded by the SBIR program. He has authored more than 100 publications and is named inventor of over 100 issued patents and several hundred pending patents. His patents were cited by MIT Magazine as being in the top 10 in the world both in 2003 and 2004 across all industries based on citation frequency. He has served on the U.S. National Research Council panel for Chemical Science and Technology at the National Institute of Standards and Technology and numerous other governmental, grant and journal review committees and boards.

In 2003 he received the ABL Innovations in HealthCare Gold award and in 2004 he received the Henry F. Whalen, Jr. Award for Business Development by the American Chemical Society. Dr. Short currently serves as a Director for Invitrogen, (NASDAQ: IVGN) Carlsbad, California, a leading biotechnology company in the area of gene expression, Senomyx (NASDAQ: SNMX), a leader in using biotechnology for the development of novel food and beverage ingredients, Nventa (TORONTO: NVN), a pioneering immune therapeutics company and Anaptys, an protein therapeutics company. He is an advisor for City National Bank and the Biotechnology Investment Group. In addition, he is a lifetime fellow of the Explorer’s Club, member of YPO and, most recently, both founder and co-owner of Capia IP, LLC, a strategic intellectual property company and BioAtla, a global protein evolution and engineering services company based in San Diego and Beijing.

Dr. Short is currently the Chairman, CEO & Principal of BioAtla, a global, protein engineering and evolution company.

He also currently serves on the Boards of Directors of Invitrogen, a biotechnology company in the area of gene expression, Senomyx, a leader in using biotechnology for the development of novel food and beverage ingredients; Anaptys, a second-generation therapeutic antibody company; and is Entrepreneur in Residence for UCSD-Connect. Dr. Short joined the Neurorepair SAB in March, 2007.

Dr. Steven Potkin

Dr. Potkin received his M.D. from Washington University in St. Louis, MO. He completed his Residency in Psychiatry at Duke University, Durham, NC.

Dr. Potkin was a Clinical Associate, Laboratory of Clinical Psychopharmacology, NIMH, St. Elizabeth’s Hospital, Washington, D.C., a Research Psychiatrist, Adult Psychiatry Branch, NIMH, Washington, D.C., and Scientific Director for International Affairs (acting), Office of the Associate Administrator for International Affairs; Alcohol, Drug Abuse and Mental Health Administration in Rockville, MD.

He is presently Assistant Chief (acting), Center for Studies of Schizophrenia, and Head, Center for Studies of Schizophrenia at NIMH.

He is also presently a Professor, Department of Psychiatry and Human Behavior, Director of Research, Department of Psychiatry and Human Behavior, and the Director of the Brain Imaging Center, all at the University of California, at Irvine. Dr. Potkin is a member of the UCSD-UCI GCRC Advisory Committee, and the Robert R. Sprague Director at the Brain Imaging Center, University of California, Irvine

Dr. Potkin has received the following honors and awards:
  • Sol Ginsburg Fellowship, Group for the Advancement of Psychiatry (GAP), 1974-76
  • A.E. Bennett Clinical Science Research Award from the Society of Biological Psychiatry, 1981
  • NIMH Foreign Work Study Fellowship, 1981-83
  • Moroccan-American Scientific Cooperation Commission Scholar, 1985
  • World Health Organization, U.S. Center for Research & Training in Biological Psychiatry, Deputy Director and Coordinator, 1988.
  • California Alliance for the Mentally Ill Outstanding Psychiatrist, 1990
  • Listed in The Best Doctors in America, Woodward/White Inc. 1994 and 1998
  • Recipient of the Riley Public Service Award, Mental Health Association of Orange County. 1999
  • NAMI Exemplary Psychiatrist Award, 1992 and 2000
  • Mitchell B. Balter Award recipient, 2001
  • American Psychiatric Association Distinguished Fellow, 2003
  • Function BIRN – U24, NIH/NCRR (S.G. Potkin, PI), 2006-2010. This project will develop technology and methods to conduct multi site functional imaging studies, and to produce a knowledge base that would not otherwise be available through single-site imaging studies. The technology includes the development and refinement of multi-site, functional imaging protocols using robust cognitive tasks; the development and refinement of algorithms to reduce inter-site variability; the use of federated, distributed databases and storage; flexible and robust image processing software integrated with these databases and storage infrastructure; tools for data querying across the distributed databases to extract subset of data from multiple sources; and the development of both classical statistical and data mining methods to reveal the patterns of imaging, clinical, and behavioral data which differentiate important population clusters. Role: PI of the overall consortium
  • Transdisciplinary Imaging Genetics Center – P20, NIH (S.G. Potkin, PI), 2004-2007. This Center is focuses on developing robust and sensitive methods of combining genetic and neuroimaging data in analysis and visualization, for a more complete understanding of genetic influences on cognitive processing. Role: PI
  • National Alliance for Medical Imaging Computing (RFA Title: National Centers for Biomedical Computing), NIH, (S.G. Potkin, UCI PI & Core 3 Co-PI), 2004-2007. This project is a multi-institutional, interdisciplinary team of computer scientists, software engineers, and medical investigators who develop computational tools for the analysis and visualization of medical image data. Dr. Potkin’s role in the NAMIC is to lead work in schizophrenic circuitry, exploring the function and dysfunction of various cortical areas as measured in PET, DTI and fMRI datasets in comparison to circuitry measurements and given genetic hypotheses. Role: UCI site PI
  • Morphometry Biomedical Informatics Research Network, NIH, NCRR, (S.G. Potkin, PI), 2004-2009. This project focuses on collecting imaging data, upload data to BIRN infrastructure; develop software for BIRN. Morphometry BIRN participants are examining neuroanatomical/imaging (MRI) correlates of neuropsychiatric illnesses in such disorders as unipolar depression, mild Alzheimer’s disease, and mild cognitive impairment. Role: UCI site PI
  • Genomic Studies in Bipolar and Major Depression, NIMH – SILVIO O. CONTE CENTER GRANT Co-I, (W. Bunney PI), 2004-2009. This research program is focused on the discovery of etiologically relevant differentially expressed genes in postmortem brain tissue from depressed patients and individually matched controls utilizing the new cDNA microarray high throughput technology. Dr. Potkin is responsible for the post-mortem brain bank and is a co-investigator.
  • Sensory Gating in Schizophrenia: Multiple Measures, NIH, 2001-2005, (J. Patterson, PI). Topical and quantitative EEG measures in normal subjects and patients with schizophrenia are being obtained to characterize the sensory gating abnormalities in schizophrenia. These EEG data are combined with clinical and neurocognitive assessments.

He is the author or co-author of dozens or peer-reviewed publications including articles in the Journal of Clinical Psychiatry and the Journal of Neuroscience.